Trial Profile

A Multi-Center Unblinded Proof-of-Concept Study of DaxibotulinumtoxinA for Migraine Prevention in High-Frequency and Chronic Migraine: the Standard Paradigm

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daxibotulinumtoxin A (Primary)
Indications Migraine; Migraine with aura; Migraine without aura
Focus Proof of concept; Therapeutic Use
Acronyms the Standard Paradigm

Most Recent Events

27 Aug 2024 Planned number of patients changed from 10 to 20.
27 Aug 2024 Status changed from recruiting to active, no longer recruiting.
21 Nov 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com